Skip to main content
Premium Trial:

Request an Annual Quote

$67 Million in First Closing of New Burrill VC Fund

NEW YORK, Oct. 24-Burrill & Company today announced the closing of a new $67 million life sciences venture capital fund.


The San Francisco-based merchant bank, which operates six other life sciences funds, expects that the Burrill Life Sciences Capital Fund will eventually hit $250 million.


The fund will invest in early- to mid-stage biotech and life sciences companies. Average investment size will range from $3 million to $10 million.


CEO G. Steven Burrill said in a statement that he expects the fund to reach its projected $250 million total during the next several months. He also said that in this difficult economic climate, the closing "is a strong endorsement both for biotech and for the Burrill & Company investment team."


Burrill had initially expected the Life Sciences fund to reach a $100 million closing in the spring of 2001. Recently, another Burrill fund has had trouble meeting its money-raising goalson schedule.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.